替尔泊肽持续治疗用于肥胖成人减重维持:SURMOUNT-4随机临床试验
SURMOUNT-4是一项在4国70个中心开展的3期随机撤药试验:783名肥胖或超重成人先接受36周开放标签替尔泊肽治疗,减重20.9%后670人随机继续替尔泊肽或换用安慰剂52周。第36至88周,替尔泊肽组体重变化-5.5%,安慰剂组+14.0%(差值-19.4%,95%CI -21.2%至-17.7%,P<0.001);替尔泊肽组89.5%维持至少80%前期减重,安慰剂组16.6%(P<0.001)。
要点
- 36周替尔泊肽导入期平均减重20.9%。
- 停用替尔泊肽后体重显著反弹,继续治疗可维持并进一步减重。
- 最常见不良事件为轻至中度胃肠道事件,替尔泊肽组更常见。
核心结论
- 在肥胖或超重成人中,停用替尔泊肽导致减重后体重显著反弹,而持续治疗可维持并增强初始减重效果。
研究设计与样本
- 3期随机撤药临床试验,在4个国家70个中心开展,包含36周开放标签替尔泊肽导入期和52周双盲安慰剂对照期。
- 纳入体重指数≥30或≥27且伴有体重相关并发症的成人,排除糖尿病患者。
- 783名参与者接受每周一次皮下最大耐受剂量(10或15 mg)替尔泊肽治疗36周,第36周时670人按1:1随机继续替尔泊肽(n=335)或换用安慰剂(n=335)治疗52周。
主要发现
- 完成36周导入期的670名参与者平均年龄48岁,473名(71%)为女性,平均体重107.3 kg,平均减重20.9%。
- 第36周至第88周平均体重变化百分比:替尔泊肽组-5.5% vs 安慰剂组14.0%,差值-19.4%(95%CI -21.2%至-17.7%),P<0.001。
- 第88周时维持导入期至少80%减重的比例:替尔泊肽组300人(89.5%)vs 安慰剂组16.6%,P<0.001。
- 第0周至第88周总体平均减重:替尔泊肽组25.3% vs 安慰剂组9.9%。
- 最常见不良事件多为轻至中度胃肠道事件,替尔泊肽组较安慰剂组更常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. OBJECTIVE: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes. INTERVENTIONS: Participants (n = 783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80% of the weight loss during the lead-in period. RESULTS: Participants (n = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo. CONCLUSIONS AND RELEVANCE: In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04660643.
引用
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870. doi:10.1001/jama.2023.24945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。